Risvutatug Rezetecan
Brain Metastasases
Nader Sanaiantibody_drug_conjugateEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
102 Active assets in the Brain Metastasases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TRASTUZUMAB Iambic Therapeutics, Inc | Phase 4 | BB |
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2/3 | BB |
Trastuzumab Deruxtecan Baptist Health South Florida | Phase 4 | BB |
Icotinib Betta Pharmaceuticals Co., Ltd. | Phase 3 | BB |
Copper Cu 64-DOTA-Trastuzumab City of Hope Medical Center | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Risvutatug Rezetecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →